- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02033980
Efficacy of NICE Classification in the Histological Evaluation of Colorectal Lesions
May 8, 2016 updated by: Zhizheng Ge, Shanghai Jiao Tong University School of Medicine
Efficacy of NICE Classification in the Histological Evaluation of Colorectal Lesions ----- a Multicenter Study in China
Recently, a new category classification (NICE classification) using non-magnified NBI has been proposed.
We design this multicenter study to evaluate the reliability and validity of the NICE classification in diagnosing colorectal polyps by Chinese endoscopists during both image and real-time process.
Study Overview
Detailed Description
Many reports have demonstrated the efficacy of narrow band imaging (NBI) with magnification in predicting the histology and invasion depth of colorectal polyps.
In China, however, the magnifying endoscope is not used in some medical centers.
Even in centers equipped with this technique, the magnifying colonoscope is not sufficiently used in daily practice.
Recently, a simple category classification (NICE classification) using non-magnified NBI has been proposed, which classifies colorectal tumors into types 1-3 based on different characteristics of color, surface pattern, and microvessels.
Type-1 is considered an index for hyperplastic lesions, type-2 is an index for adenoma or mucosal/SM scanty invasive carcinoma and type-3 is an index for deep SM invasive carcinoma.
The new classification has soon arouse attention and been validated in some centers on the efficacy of differentiating adenomatous and hyperplastic polyps.
However, most studies enrolled diminutive polyps less than 5mm and the efficacy of non-magnified NBI in differentiating type-2 and type-3 lesions has not been reported.
To promote this simple classification, we design this multicenter study to evaluate the predictive validity and performance characteristics of the non-magnified NBI in diagnosing polyps during both image and real-time process.
Study Type
Interventional
Enrollment (Anticipated)
400
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Zhizheng Ge, MD,Ph.D
- Phone Number: 86-21-58752345
- Email: zhizhengge@aliyun.com
Study Locations
-
-
-
Shanghai, China, 200001
- Recruiting
- Ren Ji Hospital, School of Medicine, Shanghai Jiaotong University
-
Principal Investigator:
- Zhizheng Ge, MD, Ph.D
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 90 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients with colorectal lesions during colonoscopy examination
- Informed consent available
Exclusion Criteria:
- Suspect of advanced colorectal cancer
- History of colorectal surgery, familial adenomatous polyposis or inflammatory bowel disease
- Poor bowel preparation
- Patients under unsuitable conditions for examination or treatment, such as acute upper gastrointestinal bleeding, noncorrectable coagulopathy, severe systemic disease, etc
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: DIAGNOSTIC
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
OTHER: colorectal lesions
All lesions will be observed with NBI and removed endoscopically or surgically for histological diagnosis.
|
All detected colorectal lesions will be examined by high-definition NBI.
For type 2 and type 3 lesions, subsequent magnifying NBI examination will be performed.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Accuracy of NICE classification in histological prediction by gastroenterological fellows
Time Frame: within two weeks after polypectomy
|
Diagnostic accuracy of gastroenterological fellows using non-magnified NBI according to NICE classification in histological prediction of polyps, compared with histologic examination
|
within two weeks after polypectomy
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Diagnostic accuracy of high-definition and magnifying NBI for type 2 and type 3 lesions.
Time Frame: two weeks after endoscopical or surgical resection
|
For lesions identified as type 2 or type 3, subsequent magnifying NBI examination will be performed by NBI experts.
Before that, experts will make their own assessment according to all the images taken by gastroenterological fellows, blind to their diagnosis.
Then experts will examine the lesions using magnifying endoscopy with NBI capability and make a new assessment.
|
two weeks after endoscopical or surgical resection
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Zhizheng Ge, MD,Ph.D, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai ,China.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2016
Primary Completion (ANTICIPATED)
June 1, 2017
Study Completion (ANTICIPATED)
August 1, 2017
Study Registration Dates
First Submitted
December 27, 2013
First Submitted That Met QC Criteria
January 9, 2014
First Posted (ESTIMATE)
January 13, 2014
Study Record Updates
Last Update Posted (ESTIMATE)
May 10, 2016
Last Update Submitted That Met QC Criteria
May 8, 2016
Last Verified
May 1, 2016
More Information
Terms related to this study
Other Study ID Numbers
- rjxh[2013]125
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Colorectal Polyps
-
Imperial College LondonCompleted
-
South Tyneside and Sunderland NHS Foundation TrustMedtronic; Newcastle University; North Wales Organisation for Randomised Trials...CompletedColonic Polyp | Colorectal Adenoma | Colorectal Polyp | Colorectal SSA | Colorectal Adenomatous Polyp | Sessile Serrated Adenoma | Sessile Colonic PolypUnited Kingdom
-
University Hospital, LimogesRecruitingCancer Colorectal | Polyps Colorectal | Endoscopic Submucosal ResectionFrance
-
University of Erlangen-Nürnberg Medical SchoolCompleted
-
Kaichun WuUnknown
-
Showa Inan General HospitalCompleted
-
Tischendorf, Jens, M.D.CompletedColorectal PolypsGermany
-
Hopital MontfortAFP Innovation FundCompletedColorectal Cancer | Colonic PolypsCanada
-
University Hospital, GhentCompletedColorectal Cancer | Colonic PolypBelgium
-
Chinese University of Hong KongCompletedColorectal Cancer | Colonic PolypHong Kong
Clinical Trials on NBI
-
Prince of Songkla UniversityCompletedColorectal Neoplasms | Colorectal PolypThailand
-
Changhai HospitalThe Second Hospital of Hebei Medical University; Air Force Military Medical... and other collaboratorsRecruitingColorectal Sessile Serrated LesionChina
-
Midwest Biomedical Research FoundationMedical University of South Carolina; Academisch Medisch Centrum - Universiteit... and other collaboratorsCompletedGastroesophageal Reflux | Barrett EsophagusUnited States, Netherlands
-
Portuguese Oncology Institute, CoimbraCompletedColorectal Cancer | Recurrence, Local NeoplasmPortugal
-
Shanghai Jiao Tong University School of MedicineBeijing Friendship Hospital; The Third Xiangya Hospital of Central South University and other collaboratorsRecruiting
-
Shanghai Jiao Tong University School of MedicineCompleted
-
The Leeds Teaching Hospitals NHS TrustUnknownUlcerative Colitis (UC)United Kingdom
-
Neurocrine BiosciencesCompletedType 1 Diabetes MellitusSpain, Finland, Canada, France, Czech Republic, Germany, South Africa, United Kingdom
-
Neurocrine BiosciencesEnrolling by invitationSCN8A Developmental and Epileptic Encephalopathy SyndromeUnited States
-
University Hospital OstravaCompletedCarcinoma in Situ | Hoarseness | Recurrent Respiratory Papillomatosis | Chronic Inflammation of Hypopharynx | Macroscopic Laryngeal Lesions | Histological Confirmation of Dysplasia | Invasive Carcinoma of Larynx | Invasive Carcinoma of Hypo PharynxCzech Republic